LoboVault Home
 

Induction of mucosal immunity using virus-like particle based vaccines

LoboVault

Please use this identifier to cite or link to this item: http://hdl.handle.net/1928/12870

Induction of mucosal immunity using virus-like particle based vaccines

Show full item record

Title: Induction of mucosal immunity using virus-like particle based vaccines
Author: Hunter, Zoe
Advisor(s): Chackerian, Bryce
Committee Member(s): Ozbun, Michelle
Prossnitz, Eric
Rubin, Robert L
Department: University of New Mexico. Biomedical Sciences Graduate Program
Subject(s): virus-like particles
CCR5
mucosal immunity
vaccine
HPV16 L2
LC Subject(s): Mucous membrane--Immunology
Viruses--Therapeutic use.
Vaccines.
Degree Level: Doctoral
Abstract: Many viral structural proteins are capable of spontaneously self-assembling into structures that resemble virus particles. These structures, called virus-like particles (VLPs), have multivalent, highly repetitive structures which are capable of inducing robust and enduring immune responses, and, therefore, can serve as the basis for effective vaccines. VLPs can be used as stand-alone vaccines targeting the viruses from which they are derived and also as platforms for presenting heterologous antigens; their ability to evoke strong antibody responses against even poorly immunogenic targets makes them an attractive model for future vaccine and drug delivery vehicle designs. Our lab developed display technologies that allow us to modify VLPs so they can present essentially any potential target antigen on its surface. These technologies have led to the development of several VLP-based vaccines that target molecules derived from microbial and self-antigens. We have previously shown that when given intramuscularly, these vaccines consistently induce high-titer serum antibodies. Here we present data showing that VLP-based vaccines are compatible with mucosal deliveries to both the genital and respiratory tracts. Specifically, we displayed peptides from the HPV16 L2 coat protein on the bacteriophage VLP platform PP7, and used a second bacteriophage VLP platform, Qβ, to target two domains of the cellular HIV coreceptor CCR5 involved in HIV binding. Vaccines targeting both the viral and self-antigens were successful at inducing mucosal and systemic immune responses, represented by the presence of IgA- and IgG-specific antibodies. The induction of both mucosal and systemic immune responses presents a particular advantage for preventing infection by pathogens transmitted at mucosal surfaces. Indeed, we determined that the L2 mucosal vaccine was successful at preventing genital pseudoviral infection in a mouse model of HPV infection. As a demonstration of the VLP’s ability to evoke strong antibody responses against a self - and therefore weakly immunogenic - molecule, we also present data indicating that immunization of macaques with our CCR5 vaccine results in the maintenance of undetectable viral loads in some animals, indicating protection from infection following a high-dose challenge with SIV. Our results provide a general method for the induction of a broad, comprehensive immune response using VLPs as vaccine platforms.
Graduation Date: May 2011
URI: http://hdl.handle.net/1928/12870

Files in this item

Files Size Format View
HunterZoe_4.13.2011Dissertation.pdf 11.71Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record

UNM Libraries

Search LoboVault


Advanced Search

Browse

My Account